AbbVie Extends RINVOQ Patent Protection to 2037 Amid Settlements with Generic Manufacturers

AbbVie's stock rose 3% after the company settled litigation with generic manufacturers, securing patent protection for RINVOQ until 2037. The settlement adds five years of patent protection beyond analysts' previous estimates, with potential discounted cash flow value of $11 to $24 per share. Wells Fargo analyst Mohit Bansal described the settlement as a "big win" for AbbVie, highlighting its extended growth runway and potential for similar settlements for other major drugs like Skyrizi.

AbbVie Inc. (NYSE: ABBV) saw its stock rise by over 3% on September 11, 2025, following the company's announcement of a patent settlement with all generic manufacturers that had filed applications for generic versions of its RINVOQ medication. This agreement extends patent protection for RINVOQ until April 2037, providing an additional five years beyond previous estimates AbbVie stock rises after securing patent protection for RINVOQ until 2037^[1].

The settlement and licensing agreements, announced on September 11, 2025, confirm that no generic upadacitinib tablets (marketed as RINVOQ) will be available in the U.S. before April 2037, assuming pediatric exclusivity is granted. These agreements are subject to standard acceleration provisions AbbVie Shares Climb Following RINVOQ Patent Settlement Through 2037^[2].

Wells Fargo analyst Mohit Bansal described the settlement as a "big win" for AbbVie. He noted that consensus estimates had previously modeled patent expiry in 2032. Bansal estimates that the extended protection could add between $11 and $24 per share in discounted cash flow value AbbVie stock rises after securing patent protection for RINVOQ until 2037^[1]. He also suggested that AbbVie’s other major drug, Skyrizi, could potentially secure a similar settlement, further strengthening the company’s long-term outlook AbbVie Shares Climb Following RINVOQ Patent Settlement Through 2037^[2].

RINVOQ is a key immunology product for AbbVie, approved for multiple inflammatory conditions such as rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. The extended patent protection for RINVOQ is expected to significantly impact AbbVie's revenue and market position, providing a substantial competitive advantage.

Analysts and investors alike are optimistic about AbbVie's prospects due to the extended market exclusivity for RINVOQ and the potential for similar settlements for other major drugs like Skyrizi. This development underscores AbbVie’s unique position in the pharmaceutical sector, with a robust pipeline of innovative products and a strong growth runway.

AbbVie's stock price reflects investor confidence in the company's ability to maintain its market leadership and extend the commercial lifespan of its key products. The extended patent protection for RINVOQ is a significant milestone that could drive continued growth and profitability for the company in the coming years.

AbbVie stock rises after securing patent protection for RINVOQ until 2037^[1]: https://www.investing.com/news/stock-market-news/abbvie-stock-rises-after-securing-patent-protection-for-rinvoq-until-2037-4235613
AbbVie Shares Climb Following RINVOQ Patent Settlement Through 2037^[2]: https://investorshub.advfn.com/market-news/article/16125/abbvie-shares-climb-following-rinvoq-patent-settlement-through-2037